FibroGen (NASDAQ:FGEN) Earns “Market Perform” Rating from William Blair

William Blair reaffirmed their market perform rating on shares of FibroGen (NASDAQ:FGEN) in a research report released on Wednesday morning,RTT News reports.

Separately, StockNews.com assumed coverage on FibroGen in a report on Wednesday, November 6th. They set a “hold” rating for the company.

FibroGen Stock Performance

NASDAQ:FGEN traded down $0.00 during mid-day trading on Wednesday, hitting $0.33. 182,782 shares of the company’s stock traded hands, compared to its average volume of 2,222,746. The company has a fifty day moving average of $0.37 and a 200 day moving average of $0.72. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93. The company has a market capitalization of $33.15 million, a P/E ratio of -0.27 and a beta of 0.72.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter last year, the business earned ($0.52) EPS. On average, research analysts expect that FibroGen will post -1.12 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

A number of hedge funds and other institutional investors have recently made changes to their positions in FGEN. Alpine Global Management LLC purchased a new stake in FibroGen in the first quarter valued at $25,000. Delap Wealth Advisory LLC purchased a new stake in shares of FibroGen in the first quarter worth about $27,000. Point72 DIFC Ltd grew its holdings in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new stake in FibroGen during the second quarter worth about $48,000. Finally, Accel Wealth Management raised its position in FibroGen by 117.5% during the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 51,645 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.